Loading...
XASX
IPD
Market cap51mUSD
Dec 05, Last price  
0.04AUD
1D
2.70%
1Q
-2.56%
Jan 2017
-96.27%
IPO
-95.48%
Name

ImpediMed Ltd

Chart & Performance

D1W1MN
XASX:IPD chart
P/E
—
P/S
6.08
EPS
—
Div Yield, %
—
Shrs. gr., 5y
27.68%
Rev. gr., 5y
17.25%
Revenues
13m
+23.31%
02,311,3992,991,9533,639,0003,887,0002,945,0002,733,0003,521,0004,844,0005,791,0005,766,0003,318,0004,155,9995,741,0008,409,00010,566,00011,344,00010,319,00012,724,000
Net income
-23m
L+17.42%
0-9,754,128-14,027,655-11,402,000-14,822,000-12,342,000-8,464,000-7,935,000-14,797,000-25,980,000-27,571,000-27,248,000-23,996,000-21,377,000-20,706,000-19,874,000-20,521,000-19,790,000-23,237,000
CFO
-15m
L-17.67%
0-7,416,381-11,786,199-10,386,000-11,299,000-11,797,000-7,675,000-6,802,000-10,757,000-22,422,000-25,566,000-23,458,000-19,588,000-19,218,000-13,258,000-15,664,000-18,049,000-17,789,000-14,645,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

ImpediMed Limited, a medical software technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. It sells its devices to hospitals and clinics. The company was incorporated in 1999 and is headquartered in Pinkenba, Australia.
URL
https://www.impedimed.com
IPO date
Oct 24, 2007
Employees
76
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT